These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23107450)

  • 21. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study.
    Mueller MM; Bialleck H; Bomke B; Brauninger S; Varga C; Seidl C; Seifried E; Tonn T; Bonig H
    Vox Sang; 2013 Jan; 104(1):46-54. PubMed ID: 22827736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Administrations of peripheral blood CD34-positive cells contribute to medial collateral ligament healing via vasculogenesis.
    Tei K; Matsumoto T; Mifune Y; Ishida K; Sasaki K; Shoji T; Kubo S; Kawamoto A; Asahara T; Kurosaka M; Kuroda R
    Stem Cells; 2008 Mar; 26(3):819-30. PubMed ID: 18192236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
    Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
    Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological characterization of CD34+ cells mobilized into peripheral blood.
    Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical ex vivo expansion of G-CSF-mobilized peripheral blood stem cells: effects of serum-free media, cytokine combinations and chemotherapy.
    Li K; Li CK; Chuen CK; Tsang KS; Fok TF; James AE; Lee SM; Shing MM; Chik KW; Yuen PM
    Eur J Haematol; 2005 Feb; 74(2):128-35. PubMed ID: 15654904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis.
    Körbling M; Reuben JM; Gao H; Lee BN; Harris DM; Cogdell D; Giralt SA; Khouri IF; Saliba RM; Champlin RE; Zhang W; Estrov Z
    Transfusion; 2006 Oct; 46(10):1795-802. PubMed ID: 17002637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of retroviral transduction efficiency in CD34+ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates.
    Hematti P; Tuchman S; Larochelle A; Metzger ME; Donahue RE; Tisdale JF
    Stem Cells; 2004; 22(6):1062-9. PubMed ID: 15536196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
    Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
    Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells.
    Dash NR; Dash SN; Routray P; Mohapatra S; Mohapatra PC
    Rejuvenation Res; 2009 Oct; 12(5):359-66. PubMed ID: 19929258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of peripheral blood CD34+ cells mobilized with granulocyte colony-stimulating factor (G-CSF) using a long-term culture system.
    Suzuki T; Muroi K; Amemiya Y; Miura Y
    Bone Marrow Transplant; 1998 Apr; 21(8):751-7. PubMed ID: 9603397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transduction of retrovirus-mediated NeoR gene into CD34+ cells purified from granulocyte colony-stimulating factor (G-CSF)-mobilized infant and cord blood.
    Abe T; Ito M; Okamoto Y; Kim HJ; Takaue Y; Yasutomo K; Makimoto A; Yamaue T; Kawano Y; Watanabe T; Shimada T; Kuroda Y
    Exp Hematol; 1997 Aug; 25(9):966-71. PubMed ID: 9257810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
    Haas R; Murea S
    Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial.
    Lee MS; Lee FY; Chen YL; Sung PH; Chiang HJ; Chen KH; Huang TH; Chen YL; Chiang JY; Yin TC; Chang HW; Yip HK
    Oncotarget; 2017 Mar; 8(11):17750-17762. PubMed ID: 28148896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of differentiation antigens and adhesion molecules on CD34+ cells in peripheral blood and bone marrow after chemotherapy followed by administration of granulocyte colony stimulating factor.
    Masauzi N
    Hokkaido Igaku Zasshi; 1996 Nov; 71(6):771-83. PubMed ID: 8996844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial.
    Tarella C; Rutella S; Gualandi F; Melazzini M; Scimè R; Petrini M; Moglia C; Ulla M; Omedé P; Bella VL; Corbo M; Silani V; Siciliano G; Mora G; Caponnetto C; Sabatelli M; Chiò A;
    Cytotherapy; 2010; 12(1):50-9. PubMed ID: 19878077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Five-Year Study of the Efficacy of Purified CD34+ Cell Therapy for Angiitis-Induced No-Option Critical Limb Ischemia.
    Fang Y; Wei Z; Chen B; Pan T; Gu S; Liu P; Guo D; Xu X; Jiang J; Yang J; Shi Z; Zhu T; Shi Y; Liu Y; Dong Z; Fu W
    Stem Cells Transl Med; 2018 Aug; 7(8):583-590. PubMed ID: 29709112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F; Cavenaghi L; de Melo CM
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
    Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
    Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcutaneous oxygen pressure as predictive parameter for ulcer healing in endstage vascular patients treated with spinal cord stimulation.
    Claeys LG; Horsch S
    Int Angiol; 1996 Dec; 15(4):344-9. PubMed ID: 9127776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.